Last reviewed · How we verify

Healive+Havrix

Sinovac Biotech Co., Ltd · FDA-approved active Biologic

Healive+Havrix is a combination vaccine that provides immunization against hepatitis A and hepatitis B through inactivated viral antigens.

Healive+Havrix is a combination vaccine that provides immunization against hepatitis A and hepatitis B through inactivated viral antigens. Used for Prevention of hepatitis A infection, Prevention of hepatitis B infection.

At a glance

Generic nameHealive+Havrix
Also known asHepatitis A vaccine
SponsorSinovac Biotech Co., Ltd
Drug classInactivated viral vaccine combination
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Healive is an inactivated hepatitis A vaccine developed by Sinovac, while Havrix is the brand name for GSK's hepatitis A vaccine. This combination formulation stimulates the immune system to produce antibodies against both hepatitis A and B viruses, providing protective immunity against infection with these pathogens. The vaccines contain inactivated (killed) virus particles or recombinant antigens that trigger humoral and cellular immune responses without causing disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: